Consent given pursuant to Sections 14 and 14A to the supply of the therapeutic goods specified by Reckitt Benckiser (Australia) Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the quality, safety, and efficacy of therapeutic goods available in the market, ensuring they meet appropriate standards and are properly labelled. This Act provides the Therapeutic Goods Administration with the authority to oversee the manufacture, importation, supply, and advertising of therapeutic goods, thus safeguarding public health. The consent granted under sections 14 and 14A of the Act allows for exceptions to certain labelling requirements for specific products, such as the temporary use of outdated sponsor information on labels, to facilitate smooth transitions or corrections in sponsorship without necessitating immediate compliance with updated regulatory standards. This provision supports the policy objective of maintaining the availability of essential therapeutic products while ensuring gradual adherence to regulatory requirements.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration, pertains to the regulation of therapeutic goods in Australia. This Act applies to various entities involved in the manufacture, supply, and distribution of therapeutic goods, ensuring that these goods meet safety, quality, and efficacy standards. It encompasses a wide range of therapeutic goods, including medicines, medical devices, blood, tissues, and other related products. The Act applies nationally, extending its reach across the Commonwealth, states, and territories of Australia. However, it excludes certain products, such as goods solely for personal use, those regulated under other Commonwealth legislation, and those exempt by the regulations. The Act also allows for the issuance of consents under specific sections, such as sections 14 and 14A, which can modify or relax certain regulatory requirements under particular circumstances, as seen in the case of the consent granted to Reckitt Benckiser (Australia) Pty Ltd regarding the labels of certain Scholl products. This consent permits the supply of products with labels that do not fully comply with certain labelling requirements, illustrating the Act's flexibility in addressing specific industry needs while maintaining overall regulatory integrity.

Key Provisions

The Therapeutic Goods Act 1989, specifically under sections 14 and 14A, allows for certain exceptions to the standard regulatory requirements for therapeutic goods. In this case, the Secretary of the Department of Health, on the application of Reckitt Benckiser (Australia) Pty Ltd, granted consent for the supply of four specific products that do not conform to the labelling requirements outlined in Therapeutic Goods Order No. 69. These products include Scholl Corn Removal Plasters Washproof, Scholl Corn Removal Pads, Scholl Callus Removal Pads, and Scholl Wart Removal System Washproof. The consent permits the use of labels that incorrectly list the previous sponsor, SSL Australia Pty Ltd, instead of the current sponsor, Reckitt Benckiser (Australia) Pty Ltd. This consent is effective from 8 September 2015 until 30 June 2016. Under the Therapeutic Goods Act 1989, the primary obligation of the entities involved is to ensure that therapeutic goods supplied in Australia meet the required standards and regulations. This includes adhering to the labelling requirements set out in the Therapeutic Goods Orders. However, the consent granted under sections 14 and 14A allows for temporary deviation from these requirements under specific conditions. For the products in question, the obligation is to supply them with labels that, while not fully compliant with the standard labelling requirements, still allow consumers to identify the products and the current sponsor accurately. The Therapeutic Goods Act 1989 imposes several obligations on entities that supply therapeutic goods in Australia. These include ensuring that products are safe, of acceptable quality, and that their labelling accurately reflects the sponsor's details. The consent granted under sections 14 and 14A requires Reckitt Benckiser (Australia) Pty Ltd to ensure that the products supplied during the consent period have labels that, while not fully compliant, still provide essential information to consumers. This includes the product names and the current sponsor's details. Failure to comply with the Therapeutic Goods Act 1989 or the Therapeutic Goods Orders can result in various penalties and consequences. Under section 35 of the Act, supplying goods that do not comply with the requirements can result in civil penalties. The maximum penalty for a corporation can be up to $2,100,000 for each day the offence continues. Criminal penalties can also apply, with individuals potentially facing fines of up to $210,000 and imprisonment for up to five years. The consent granted under sections 14 and 14A is a temporary measure and does not exempt the supplier from these penalties if the conditions of the consent are not adhered to.